Genetic risk factors for Clostridium difficile infection in ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 5, 2013, Pages 522-530

  Ananthakrishnan, A N ^a,b   Oxford, E C ^c   Nguyen, D D ^a,b   Sauk, J ^a,b   Yajnik, V ^a,b   Xavier, R J ^a,b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; GENE LOCUS; GENETIC RISK; GENOTYPE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PANCOLITIS; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; ULCERATIVE COLITIS;

EID: 84882455083     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12425     Document Type: Article

References (49)

1. Ananthakrishnan AN,. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011; 8: 17-26.
2. Bartlett JG,. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008; 46 (Suppl. 1): S4-11.
3. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB,. Antibiotic-Associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298: 531-4.
4. Kelly CP,. A 76-year-old man with recurrent Clostridium difficile-Associated diarrhea: review of C. difficile infection. JAMA 2009; 301: 954-62.
5. McFarland LV,. Renewed interest in a difficult disease: Clostridium difficile infections-epidemiology and current treatment strategies. Curr Opin Gastroenterol 2009; 25: 24-35.
6. Monaghan T, Boswell T, Mahida YR,. Recent advances in Clostridium difficile-Associated disease. Gut 2008; 57: 850-60.
7. Pepin J, Valiquette L, Alary ME, et al,. Clostridium difficile-Associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-72.
8. Rupnik M, Wilcox MH, Gerding DN,. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526-36.
9. Wilcox MH, Cunniffe JG, Trundle C, Redpath C,. Financial burden of hospital-Acquired Clostridium difficile infection. J Hosp Infect 1996; 34: 23-30.
10. Pepin J, Alary ME, Valiquette L, et al,. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-7.
11. Pepin J, Saheb N, Coulombe MA, et al,. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-Associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-60.
12. Pepin J, Valiquette L, Cossette B,. Mortality attributable to nosocomial Clostridium difficile-Associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173: 1037-42.
13. Kyne L, Warny M, Qamar A, Kelly CP,. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390-7.
14. Loo VG, Poirier L, Miller MA, et al,. A predominantly clonal multi-institutional outbreak of Clostridium difficile-Associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-9.
15. Kelly CP, Kyne L,. The host immune response to Clostridium difficile. J Med Microbiol 2011; 60: 1070-9.
16. Bignardi GE,. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40: 1-15.
17. Britton RA, Young VB,. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol 2012; 20: 313-9.
18. Diggs NG, Surawicz CM,. Evolving concepts in Clostridium difficile colitis. Curr Gastroenterol Rep 2009; 11: 400-5.
19. Rodemann JF, Dubberke ER, Reske KA, da Seo H, Stone CD,. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-44.
20. Issa M, Ananthakrishnan AN, Binion DG,. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1432-42.
21. Ananthakrishnan AN, Issa M, Binion DG,. Clostridium difficile and inflammatory bowel disease. Gastroenterol Clin North Am 2009; 38: 711-28.
22. Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG,. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 976-83.
23. Ananthakrishnan AN, Guzman-Perez R, Gainer V, et al,. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 789-95.
24. Jen MH, Saxena S, Bottle A, Aylin P, Pollok RC,. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 1322-31.
25. Murthy SK, Steinhart AH, Tinmouth J, Austin PC, Daneman N, Nguyen GC,. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther 2012; 36: 1032-9.
26. Ananthakrishnan AN, McGinley EL, Binion DG,. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205-10.
27. Issa M, Vijayapal A, Graham MB, et al,. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-51.
28. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B,. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253-64.
29. Pascarella F, Martinelli M, Miele E, Del Pezzo M, Roscetto E, Staiano A,. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009; 154: 854-8.
30. Powell N, Jung SE, Krishnan B,. Clostridium difficile infection and inflammatory bowel disease: a marker for disease extent? Gut 2008; 57: 1183-4; author reply 1184.
31. Jostins L, Ripke S, Weersma RK, et al,. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-24.
32. Khor B, Gardet A, Xavier RJ,. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-17.
33. Cortes A, Brown MA,. Promise and pitfalls of the Immunochip. Arthritis Res Ther 2011; 13: 101.
34. Shah TS, Liu JZ, Floyd JA, et al,. optiCall: a robust genotype-calling algorithm for rare, low-frequency and common variants. Bioinformatics 2012; 28: 1598-603.
35. Purcell S, Neale B, Todd-Brown K, et al,. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-75.
36. Jodorkovsky D, Young Y, Abreu MT,. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010; 55: 415-20.
37. Kyne L, Warny M, Qamar A, Kelly CP,. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189-93.
38. Lowy I, Molrine DC, Leav BA, et al,. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197-205.
39. Lee JY, Kim H, Cha MY, et al,. Clostridium difficile toxin A promotes dendritic cell maturation and chemokine CXCL2 expression through p38, IKK, and the NF-kappaB signaling pathway. J Mol Med (Berl) 2009; 87: 169-80.
40. Kim H, Kokkotou E, Na X, et al,. Clostridium difficile toxin A-induced colonocyte apoptosis involves p53-dependent p21(WAF1/CIP1) induction via p38 mitogen-Activated protein kinase. Gastroenterology 2005; 129: 1875-88.
41. Schaer C, Hiltbrunner S, Ernst B, et al,. HVEM signalling promotes colitis. PLoS One 2011; 6: e18495.
42. Shui JW, Larange A, Kim G, et al,. HVEM signalling at mucosal barriers provides host defence against pathogenic bacteria. Nature 2012; 488: 222-5.
43. Cifaldi L, Romania P, Lorenzi S, Locatelli F, Fruci D,. Role of endoplasmic reticulum aminopeptidases in health and disease: from infection to cancer. Int J Mol Sci 2012; 13: 8338-52.
44. Nakada TA, Russell JA, Wellman H, et al,. Leucyl/cystinyl aminopeptidase gene variants in septic shock. Chest 2011; 139: 1042-9.
45. Chew V, Lam KP,. Leupaxin negatively regulates B cell receptor signaling. J Biol Chem 2007; 282: 27181-91.
46. Meggyesi N, Kiss LS, Koszarska M, et al,. NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients. World J Gastroenterol 2010; 16: 5233-40.
47. Pabst O, Zweigerdt R, Arnold HH,. Targeted disruption of the homeobox transcription factor Nk2-3 in mice results in postnatal lethality and abnormal development of small intestine and spleen. Development 1999; 126: 2215-25.
48. Kim JM, Lee JY, Yoon YM, Oh YK, Youn J, Kim YJ,. NF-kappa B activation pathway is essential for the chemokine expression in intestinal epithelial cells stimulated with Clostridium difficile toxin A. Scand J Immunol 2006; 63: 453-60.
49. Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ,. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009; 15: 1053-66.